<DOC>
	<DOCNO>NCT00003877</DOCNO>
	<brief_summary>RATIONALE : Peripheral stem cell transplantation may allow doctor give high dos chemotherapy kill tumor cell . It yet know whether Stromagen improve success stem cell transplantation woman breast cancer . PURPOSE : Randomized phase I/II trial study effectiveness Stromagen stem cell transplantation follow chemotherapy treat woman metastatic breast cancer .</brief_summary>
	<brief_title>Peripheral Stem Cell Transplantation With Without Stromagen Following Chemotherapy Treating Women With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety expand mesenchymal stem cell ( Stromagen ) infusion autologous CD34+ peripheral blood stem cell transplantation high dose chemotherapy woman metastatic breast cancer . II . Compare time neutrophil platelet engraftment patient receive different dos Stromagen . III . Evaluate immune reconstitution patient therapy . OUTLINE : This randomize , placebo control , blind study . Patients randomly assign one three treatment arm . All patient undergo mobilization peripheral blood stem cell ( PBSC ) use cyclophosphamide IV 1 hour paclitaxel IV 3 hour day 1 , filgrastim ( G-CSF ) subcutaneously begin day 4 continue completion leukapheresis . PBSC bone marrow cell collect CD34 positive cell select . About 4 week later , patient receive high dose chemotherapy . Cyclophosphamide IV 24 hour , carboplatin IV 24 hour , thiotepa IV 24 hour administer day -7 -4 . Patients receive placebo one two dos expand mesenchymal stem cell ( Stromagen ) IV day -1 CD34+ select PBSC IV 2 hour day 0 . Patients follow 6 week 12 week , 1 year . PROJECTED ACCRUAL : A total 30 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven metastatic breast cancer involve least 1 bone site Completed induction chemotherapy No active CNS disease Hormone receptor status : Estrogen receptor progesterone receptor negative OR Hormone refractory disease PATIENT CHARACTERISTICS : Age : 18 64 Sex : Female Menopausal status : Not specify Performance status : Not specify Life expectancy : Not specify Hematopoietic : WBC great 1000/mm3 Platelet count great 100,000/mm3 Hepatic : Hepatitis B surface antigen negative Hepatitis C negative No cirrhosis Renal : Creatinine le 2.0 mg/dL OR Creatinine clearance great 50 mL/min Cardiovascular : Cardiac ejection fraction great 50 % MUGA Pulmonary : DLCO great 50 % Other : Not pregnant Fertile patient must use effective contraception No active infection No active alcohol substance abuse within 6 month At least 1 year since clinically significant CNS disease seizures HIV negative No medical condition would preclude evaluation patient PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Endocrine therapy : See Disease Characteristics Radiotherapy : At least 3 year since prior radiotherapy , except local adjuvant therapy Surgery : Not specify</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>